VERAXA (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has reached another development milestone in its oncology pipeline, announcing that its VXA-222 bispecific antibody-drug conjugate (“bsADC”) program has advanced beyond the discovery phase and into the next stage of development. The milestone reflects continued progress across the company’s therapeutic portfolio as it simultaneously expands the intellectual property supporting its next generation of antibody-based cancer therapies.
The announcement marks the successful completion of the discovery portion of VERAXA’s collaboration with OmniAb Inc., which began in May 2025 (https://nnw.fm/nIprz). With the discovery work completed, VERAXA will now focus on building the final therapeutic candidate by combining the antibody binders identified through the collaboration with its own proprietary antibody engineering, linker, and conjugation technologies. Although VXA-222 is not based on VERAXA’s BiTAC platform, it leverages these technologies and represents one of the company’s more advanced development programs.
In addition to the VXA-222 progress, VERAXA recently expanded its intellectual property portfolio with its first BiTAC-related patent filings, alongside additional patents supporting conjugation chemistry, payloads, and antibody technologies. The company now holds more than 50 granted owned or exclusively licensed patents across 26 patent families in 14 countries, with newly filed applications expected to extend protection into at least 2047. This robust IP estate is crucial for protecting the company’s innovative approaches and maintaining a competitive edge in the rapidly evolving field of antibody-based cancer therapeutics.
VERAXA continues to build a diversified oncology pipeline spanning bispecific antibody-drug conjugates, T-cell engagers, and engineered antibody formats targeting difficult-to-treat cancers. The advancement of VXA-222 and the expansion of its patent portfolio underscore the company’s commitment to addressing significant unmet medical needs and creating value for patients and shareholders alike.
The completion of the discovery phase with OmniAb is a key step in the development of VXA-222, as it provides a portfolio of therapeutic antibody binders that will be engineered into a final bispecific ADC candidate. VERAXA will now conduct preclinical validation, aiming to advance this promising candidate into clinical trials. The success of VXA-222 could offer a new treatment option for patients with hard-to-treat cancers, potentially improving outcomes and quality of life.
The expansion of VERAXA’s patent portfolio is equally significant, as it strengthens the company’s position in the competitive landscape of cancer immunotherapy. With patents covering various aspects of its technology, including BiTAC and conjugation chemistries, VERAXA is well-positioned to safeguard its innovations and potentially generate revenue through licensing agreements. The extended patent protection into at least 2047 provides long-term security for the company’s pipeline and commercial prospects.
Investors and industry observers will be watching closely as VERAXA advances VXA-222 and other pipeline candidates. The company’s strategic focus on developing next-generation antibody technologies, combined with its robust IP strategy, positions it for potential growth in the oncology market. As VERAXA continues to achieve milestones, it may attract further attention from partners and investors seeking to capitalize on the growing demand for targeted cancer therapies.
